A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Part of paid clinical trials in Lincoln, Nebraska.
- Sponsor
- Merck Sharp & Dohme LLC
- Study ID
- NCT07554339
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Calderasib — DRUGTablet for oral administration.
- Durvalumab — BIOLOGICALSolution for intravenous (IV) infusion.
- Placebo to MK-1084 — OTHERPlacebo to MK-1084.
Study Details
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.
Key Dates
- First listed
- Apr 28, 2026
- Start date
- Jun 18, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 15, 2032
- Completion
- Aug 17, 2037
Study Design
- Enrollment
- 310 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Calderasib + DurvalumabParticipants will receive calderasib and durvalumab.
- Active Comparator: Placebo + DurvalumabParticipants will receive placebo to calderasib and durvalumab.
Primary Outcome Measure
Progression-Free Survival (PFS) [ Time Frame: Up to approximately 6 years ]
Central Contacts
- Toll Free Number1-888-577-8839
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NHO Revive Research Institute LLC ( Site 0118) | Lincoln | Nebraska | 68506 | Study Coordinator 402-484-4900 |
| New York Oncology Hematology P.C ( Site 9000) | Albany | New York | 12206 | Study Coordinator 518-489-0044 |
Find similar trials in Lincoln, NE
By condition
By specialty
Related Studies
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · Savannah, Georgia
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)PHASE1/PHASE2 · Recruiting · Inhibrx Biosciences, Inc · Duarte, California